Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Le Qin

Showing results (171-180 of 178) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 178 results.
Molecular Therapy Oncolytics|July 5, 2022
DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2DShanglin Li, Ruocong Zhao, Diwei Zheng, et al.
Nature Communications|October 13, 2022
Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axisLe Qin, Yuanbin Cui, Tingjie Yuan, et al.
Cell Reports. Medicine|March 19, 2025
CD4<sup>+</sup> anti-TGF-β CAR T cells and CD8<sup>+</sup> conventional CAR T cells exhibit synergistic antitumor effectsDiwei Zheng, Le Qin, Jiang Lv, et al.
Cell Reports|July 12, 2023
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.
Leukemia|November 10, 2020
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cellsZhiwu Jiang, Rui Liao, Jiang Lv, et al.
Biomarker Research|March 25, 2022
Human induced-T-to-natural killer cells have potent anti-tumour activitiesZhiwu Jiang, Le Qin, Yuou Tang, et al.
Journal of Hematology & Oncology|July 30, 2021
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelinNengzhi Pang, Jingxuan Shi, Le Qin, et al.
Translational Lung Cancer Research|September 21, 2020
COVID-19 and early-stage lung cancer both featuring ground-glass opacities: a propensity score-matched studyYa-Jie Zhang, Wen-Jie Yang, Dong Liu, et al.
Pageof 18

Showing results (171-180 of 178) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Molecular Therapy Oncolytics|July 5, 2022
DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2DShanglin Li, Ruocong Zhao, Diwei Zheng, et al.
Nature Communications|October 13, 2022
Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axisLe Qin, Yuanbin Cui, Tingjie Yuan, et al.
Cell Reports. Medicine|March 19, 2025
CD4<sup>+</sup> anti-TGF-β CAR T cells and CD8<sup>+</sup> conventional CAR T cells exhibit synergistic antitumor effectsDiwei Zheng, Le Qin, Jiang Lv, et al.
Cell Reports|July 12, 2023
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.
Leukemia|November 10, 2020
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cellsZhiwu Jiang, Rui Liao, Jiang Lv, et al.
Biomarker Research|March 25, 2022
Human induced-T-to-natural killer cells have potent anti-tumour activitiesZhiwu Jiang, Le Qin, Yuou Tang, et al.
Journal of Hematology & Oncology|July 30, 2021
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelinNengzhi Pang, Jingxuan Shi, Le Qin, et al.
Translational Lung Cancer Research|September 21, 2020
COVID-19 and early-stage lung cancer both featuring ground-glass opacities: a propensity score-matched studyYa-Jie Zhang, Wen-Jie Yang, Dong Liu, et al.
Pageof 18